Loading
institutionsInstitution
Medicines and Healthcare products Regulatory Agency
The UK medicines and devices regulator, which since Brexit runs its own approvals, joins Project Orbis and uses international reliance routes to speed cancer drug access.
Also called: MHRA
Overview
Formed in 2003 by merging the Medicines Control Agency and the Medical Devices Agency, the MHRA became the UK's standalone regulator for new medicines after the UK left the EU in 2021. It participates in the FDA-led Project Orbis and the Access Consortium (with Australia, Canada, Singapore and Switzerland), uses the International Recognition Procedure to rely on approvals by trusted regulators, and runs the Innovative Licensing and Access Pathway with NICE and the Scottish Medicines Consortium to align licensing and reimbursement. The MHRA also regulates clinical trials, devices including AI software, and blood and tissue products, and operates the Yellow Card safety scheme.
Location
London, GB
Type
government
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#378 · 16 points (0 Newsweek + 0 NCI + 16 from 8 linked objects) · ranking
- Project Orbis and Access Consortium
- International Recognition Procedure
- Innovative Licensing and Access Pathway (with NICE and SMC)
- Clinical trials and device regulation
Similar pages
- IdeaContinuous prospective validation for every oncology AI tool after deployment
Shares AI that is built but not validated or deployed, AI in radiology, Digital pathology & AI, Regulatory divergence between regions.
- InstitutionPaul-Ehrlich-Institut
Shares Bundesinstitut für Arzneimittel und Medizinprodukte, European Medicines Agency, Regulatory divergence between regions.
- IdeaDrop the extra switching studies for interchangeable oncology biosimilars
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- TermNICE technology appraisal methods (2022)
Shares Scottish Medicines Consortium, ILAP (Innovative Licensing and Access Pathway), National Institute for Health and Care Excellence.
- InstitutionComisión Federal para la Protección contra Riesgos Sanitarios
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- IdeaA dedicated fund for randomised trials of cancer AI with patient outcomes
Shares AI that is built but not validated or deployed, AI in radiology, Digital pathology & AI.
- TermProject Orbis
Shares Medicines and Medical Devices Act 2021, ILAP (Innovative Licensing and Access Pathway).
- TermClinical Trials Regulation (EU) No 536/2014 and CTIS
Shares Medicines and Medical Devices Act 2021, European Medicines Agency, Regulatory divergence between regions.